Ventvil Phase I injection safety trial registration (HEP-VTL-01)
Planned study · 2017
- Registered population or design
- 52 healthy volunteers listed in the registration. An analyzed sample and arm sizes are unavailable.
- Results availability
- The Phase I registration lists 52 healthy volunteers and describes a double-blind placebo-controlled study of injection safety and tolerability. Clinical results remain unavailable.
Study data at a glance
- Participants or experimental model
- 52 healthy volunteers listed in the registration. An analyzed sample and arm sizes are unavailable.
- Dose, route and schedule
- Double-blind randomized placebo comparison of escalating single and repeat intramuscular doses. Dose levels and allocation are unavailable in the public entry.
- Registered study design
- The Phase I registration lists 52 healthy volunteers and describes a double-blind placebo-controlled study of injection safety and tolerability. Clinical results remain unavailable.
Protocol source ↗ · Registry entry for HEP-VTL-01
Study limitations and source details
Study limitations
- The public record lists the study as completed and supplies no group-level safety results or verified analyzed denominator.
Source details
Clinical trial registration
Registry entry and contemporary sponsor announcement
Sources checked
Added to the library
Citation
SIA Peptides (sponsor). Ventvil Phase I injection safety trial registration (HEP-VTL-01) Russian clinical-trial register mirror. Authorization No. 581, 3 November 2017